Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)
View/ Open
Date
2017-04-01ICR Author
Author
Andronis, L
Goranitis, I
Pirrie, S
Pope, A
Barton, D
Collins, S
Daunton, A
McLaren, D
O'Sullivan, JM
Parker, C
Porfiri, E
Staffurth, J
Stanley, A
Wylie, J
Beesley, S
Birtle, A
Brown, JE
Chakraborti, P
Hussain, SA
Russell, JM
Billingham, LJ
James, ND
Type
Journal Article
Metadata
Show full item recordCollections
Subject
castrate-refractory prostate cancer
cost-effectiveness analysis
quality of life
bone protecting treatments
zoledronic acid
Sr89
Research team
Prostate and Bladder Cancer Research
Language
eng
Date accepted
2016-06-03
License start date
2017-04
Citation
BJU INTERNATIONAL, 2017, 119 (4), pp. 522 - 529